What is AntiCancer?
AntiCancer, Inc. is a prominent biotechnology company with over 36 years of experience, specializing in advanced cancer research and the development of preclinical models. The company is particularly recognized for its orthotopic patient-derived xenograft (PDOX) models, offering a suite of products and services that include fluorescent cell lines, various mouse models, and contract research services essential for drug discovery and evaluation. With a strong focus on methioninase research and a history validated by numerous clinical trials and over 1100 scientific publications, AntiCancer serves the pharmaceutical and research sectors by providing sophisticated solutions for cancer therapy development.
How much funding has AntiCancer raised?
AntiCancer has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
What's next for AntiCancer?
The substantial expansion capital received by AntiCancer, situated at a significant Series B/C stage, indicates a strategic push towards scaling its operations and potentially accelerating its pipeline of innovative cancer therapies. This investment is expected to fuel further research and development, enhance its preclinical model offerings, and broaden its market reach within the pharmaceutical and research communities. The company's established expertise and extensive publication record position it for continued advancement in the competitive field of oncology.
See full AntiCancer company page
